Literature DB >> 10450921

Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells.

T Minko1, P Kopecková, J Kopecek.   

Abstract

PURPOSE: To study peculiarities and the mechanism of the anticancer effect of free and HPMA copolymer-bound ADR in sensitive and resistant human ovarian carcinoma cells.
METHODS: Sensitive A2780 and ADR resistant A2780/AD cells were exposed to different doses of drugs during 12, 24, 36, 48, 60, and 72 hours. Cell viability, drug accumulation, apoptosis, cellular metabolism, lipid peroxidation, DNA content and gene expression were studied.
RESULTS: HPMA copolymer-bound ADR (P(GFLG)-ADR) possessed a comparable cytotoxicity to free ADR when comparison was based on intracellular concentrations. While free ADR up-regulated genes encoding ATP driven efflux pumps (MDR1, MRP), P(GFLG)-ADR overcame existing pumps and down regulated the MRP gene. Free ADR also activated cell metabolism and expression of genes responsible for detoxification and DNA repair. P(GFLG)-ADR down-regulated HSP-70, GST-pi, BUDP, Topo-IIalpha, beta, and TK-1 genes. Apoptosis, lipid peroxidation and DNA damage were significantly higher after exposure to P(GFLG)-ADR, as reflected by simultaneous activation of p53, c-fos in A2780 cells) or c-jun (A2780/AD) signaling pathways and inhibition of the bcl-2 gene. Differences between free ADR and P(GFLG)-ADR increased with the time of incubation and drug concentration.
CONCLUSIONS: P(GFLG)-ADR overcame drug efflux pumps, more significantly induced apoptosis and lipid peroxidation, inhibited DNA repair, replication, and biosynthesis when compared to free ADR.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450921     DOI: 10.1023/a:1018959029186

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  25 in total

1.  HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro.

Authors:  V Omelyanenko; C Gentry; P Kopecková; J Kopecek
Journal:  Int J Cancer       Date:  1998-02-09       Impact factor: 7.396

2.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

3.  HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line.

Authors:  K Kunath; P Kopecková; T Minko; J Kopecek
Journal:  Eur J Pharm Biopharm       Date:  2000-01       Impact factor: 5.571

4.  Expression of multidrug resistance-related genes (mdrl, MRP, GST-pi and DNA topoisomerase II) in urothelial cancers.

Authors:  W J Kim; Y Kakehi; W J Wu; M Fukumoto; O Yoshida
Journal:  Br J Urol       Date:  1996-09

5.  HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.

Authors:  T Minko; P Kopecková; V Pozharov; J Kopecek
Journal:  J Control Release       Date:  1998-07-31       Impact factor: 9.776

6.  C-fos expression in vivo in human lymphocytes in response to stress.

Authors:  J E Platt; X He; D Tang; J Slater; M Goldstein
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1995-01       Impact factor: 5.067

7.  Sublethal heat shock and cyclosporine exposure produce tolerance against subsequent cyclosporine toxicity.

Authors:  C M Yuan; E M Bohen; F Musio; M A Carome
Journal:  Am J Physiol       Date:  1996-09

8.  Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells.

Authors:  H J Ryser; W C Shen
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

9.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability.

Authors:  F Denizot; R Lang
Journal:  J Immunol Methods       Date:  1986-05-22       Impact factor: 2.303

10.  Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.

Authors:  K E Noonan; C Beck; T A Holzmayer; J E Chin; J S Wunder; I L Andrulis; A F Gazdar; C L Willman; B Griffith; D D Von Hoff; I B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

View more
  28 in total

Review 1.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

2.  Synthesis and characterization of poly(ε-caprolactone)-block-poly[N-(2-hydroxypropyl)methacrylamide] micelles for drug delivery.

Authors:  Stefan G Krimmer; Huaizhong Pan; Jihua Liu; Jiyuan Yang; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2011-05-12       Impact factor: 4.979

3.  Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates.

Authors:  Yuji Kasuya; Zheng-Rong Lu; Pavla Kopecková; S Esmail Tabibi; Jindrich Kopecek
Journal:  Pharm Res       Date:  2002-02       Impact factor: 4.200

Review 4.  Design of smart HPMA copolymer-based nanomedicines.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

5.  Intracellular trafficking and subcellular distribution of a large array of HPMA copolymers.

Authors:  Jon Callahan; Pavla Kopečkov; Jindřich Kopeček
Journal:  Biomacromolecules       Date:  2009-05-21       Impact factor: 6.988

6.  POLYMERIC BIOMATERIALS AND NANOMEDICINES.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Drug Deliv Sci Technol       Date:  2015-12-01       Impact factor: 3.981

Review 7.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.

Authors:  Darren Lars Stirland; Joseph W Nichols; Seiji Miura; You Han Bae
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

8.  Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.

Authors:  Rui Zhang; Jiyuan Yang; Monika Sima; Yan Zhou; Jindřich Kopeček
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

9.  Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.

Authors:  Alex M Chen; Min Zhang; Dongguang Wei; Dirk Stueber; Oleh Taratula; Tamara Minko; Huixin He
Journal:  Small       Date:  2009-12       Impact factor: 13.281

10.  A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance.

Authors:  Gene L Bidwell; Aisha N Davis; Izabela Fokt; Waldemar Priebe; Drazen Raucher
Journal:  Invest New Drugs       Date:  2007-05-05       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.